The Genetics Podcast

The Genetics Podcast

By Sano GeneticsScienceNatural Sciences
Download on the App Store

All The Genetics Podcast episodes

  • EP 266: How patient communities are accelerating rare disease research with Tania Simoncelli of Biohub

    This week on The Genetics Podcast, Patrick is joined by Tania Simoncelli, Vice President of Translational Impact and Engagement at Biohub. They discuss how patient-led organizations drive rare disease research, the capacity building and partnerships behind the Rare As One network, how AI could change drug repurposing and clinical trials, and Tania’s role in the ACLU case against human gene patents.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to Tania

    01:41 The founding story and aim of the Rare As One Project

    05:17 Impact and scale of the Rare As One network, from funding to clinical trials

    10:45 Why cycle four focuses on rare respiratory, immune dysregulation and sarcoma communities

    14:54 How rare disease data and patient networks connect to Biohub’s virtual cell and AI models 

    19:00 The Rare As One partnership with Every Cure on AI-driven drug repurposing 

    24:29 Rare As One partnerships with the Broad Institute, Citizen Health and the Fowler lab

    28:49 Organizational and scientific capacity building for patient-led rare disease organizations

    34:03 Tania’s ACLU case against human gene patents and its impact 

    43:26 How patient communities are adopting AI and where it could take rare disease research

    46:33 Closing remarks

    48 min
  • EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp

    This week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:58 Welcome to Joe 

    01:47 Joe’s career in HIV genetics and his move into neurology

    06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau217

    11:04 Why p-tau217 works as a scalable Alzheimer’s blood test

    12:35 How p-tau217 triages patients and what it can’t tell clinicians

    14:08 APOE testing demand and why it predicts risk without being definitive

    17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown

    21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took

    24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers

    27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau217

    29:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for

    34:27 How Labcorp decides which neurology biomarkers to launch and when

    38:12 Future potential for migraine biomarkers that can guide treatment choices

    41:07 Closing remarks

    43 min
  • EP 264: What AI’s math breakthroughs mean for drug development and genetics

    This week on The Genetics Podcast, Patrick goes solo to look at what recent AI breakthroughs in mathematics could mean for biology. He discusses the OpenAI results on the Navier-Stokes equation and hundreds of open math problems, what makes math and code so easy for AI to improve on, how self-driving labs and surrogate endpoints could speed up drug development, and where the biggest gaps and opportunities remain.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:58 What the OpenAI math breakthroughs could mean for biology

    02:57 AI’s recent frontier math results and how mathematicians reacted

    09:12 Lean as a proof checker and why it matters for math

    10:44 Four conditions behind AI’s math progress and how biology compares

    16:22 Why verification speed decides where AI can accelerate biology

    19:35 How lab automation shortens feedback loops for variants and antibodies

    23:13 How validated biomarkers let early trials predict clinical outcomes

    26:11 Why validated surrogate endpoints could speed up drug development

    31:58 How startups and big pharma are building self-driving labs

    33:40 Virtual cell models built from perturbation data

    34:50 Genetics-driven drug discovery and the Phase II success rate question

    37:42 Verification speed and surrogate endpoints as biology’s biggest gaps

    40:38 Closing remarks

    42 min
  • EP 263: Bringing the first cardiovascular gene editing therapy to patients with Sek Kathiresan of Eli Lilly

    This week on The Genetics Podcast, Patrick is joined by Dr. Sek Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Research and Early Development at Eli Lilly. They discuss how protective genetic variants led to the development of a one-time gene editing therapy for heart disease in the face of early doubt, the phase one results for Verve-102, what recent trial failures mean for genetic target validation, and the unmet needs in obesity treatment.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to Sek 

    01:40 Sek’s family history of heart disease and how it motivated him to pursue cardio therapeutics

    03:29 Sek’s background and research on the genetics of coronary artery disease and protective mutations

    08:03 Reactions to the Verve launch and the biological, technological, regulatory, and commercial risks

    11:00 Verve-102 phase one results and the case for lifelong LDL lowering

    16:14 Why cumulative exposure means lowering LDL earlier and for longer

    17:53 Recent trial failures in genetically validated targets and what the Lp(a) trial leaves unanswered

    20:33 Polygenic risk scores and who benefits most from LDL lowering

    23:36 Sek’s new role at Lilly and the remaining unmet needs in obesity treatment

    29:06 Whether one-time gene therapy could work for obesity and how GLP-1 drugs drive weight loss

    30:38 Food intake, energy expenditure, and the search for new obesity mechanisms

    32:15 Why Lilly is investing so heavily in genetic medicine

    34:35 Closing remarks

    Find out more

    • ANGPTL3 study in NEJM (https://pmc.ncbi.nlm.nih.gov/articles/PMC3008575/)

    • Verve-102 study (https://www.nejm.org/doi/10.1056/NEJMoa2601283)

    37 min
  • EP 262: The genetic drivers of hemochromatosis, drug response, and multimorbidity with Luke Pilling of the University of Exeter

    This week on The Genetics Podcast, Patrick is joined by Dr. Luke Pilling, Senior Lecturer in Genetic Epidemiology at the University of Exeter. They discuss hemochromatosis and the case for earlier diagnosis, and the genetic drivers of multimorbidity, pharmacogenetics, and drug response.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to Luke 

    01:37 An overview of HFE hemochromatosis and why diagnosis is delayed 

    04:24 Iron levels and overload risk in heterozygous and compound heterozygous carriers

    05:51 Aging-related effects seen in homozygotes 

    06:43 How hemochromatosis is currently diagnosed and detected in the UK

    09:26 Future screening and case finding, including the Our Future Health cohort

    11:28 Genetic and environmental factors that shape outcomes in C282Y homozygotes 

    13:28 The GEMINI project and the genetic drivers of multimorbidity

    15:56 Drug targets from multimorbidity genetics, including repurposing and opposite effects

    18:49 Using disease sequences in health records to look for earlier intervention points in multimorbidity

    21:21 Data gaps limiting multimorbidity research, from primary care records to proteomics

    23:17 Handling misdiagnosis and clinical code accuracy in health record research

    24:55 International collaborations and the need for more diverse biobank data

    26:08 Pharmacogenetics research and how genetic variants shape drug response

    29:04 Limited clinical examples of pharmacogenetics and lessons from non-responders

    33:08 Genetics of lifespan and healthy aging, and why geroscience pathways rarely appear in GWAS

    36:06 Luke’s future research focuses 

    40:39 Closing remarks

    Find out more:

    - Hereditary hemochromatosis study

    - Multimorbidity study

    - Pharmacogenetics framework study

    39 min
  • EP 261: Inside the virtual biotech staffed by AI agents with James Zou of Stanford University

    This week on The Genetics Podcast, Patrick is joined by Dr. James Zou, Associate Professor of Biomedical Data Science at Stanford University. They discuss the concept of virtual biotechs and how AI agents link single cell data to clinical trial success, Paper to Agent and turning papers into living virtual authors, clinical AI from EchoNet to SleepFM, and the role of academia alongside big AI labs.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to James 

    01:55 An overview of James’s virtual biotech and its AI scientist agents

    04:11 How single cell evidence behind drug targets predicts clinical trial success

    06:33 Behind the scenes of how autonomous the virtual biotech agents are

    08:06 Missing proprietary trial data as the next gap for the virtual biotech

    09:44 Scaling the number of collaborating AI agents as a new frontier for drug discovery

    12:29 How teamwork and structure evolved among the agents 

    15:53 Behind the idea of Paper to Agent and virtual authors

    19:01 What converting over 100 papers into agents revealed about reproducibility

    23:14 The story behind EchoNet, an FDA-cleared AI tool for cardiac ultrasound

    26:28 Predicting risk for over 100 future diseases from one night of sleep

    27:40 Transferring SleepFM from sleep labs to consumer wearables

    28:43 Combining multimodal health data to predict disease

    30:10 Longitudinal blood proteomics as the biggest data gap for health AI

    31:18 The role of academia as an open, neutral counterweight to big AI labs

    32:51 How James’s path from Cambridge math and Harvard machine learning led to biology

    34:41 Closing remarks

    Find out more

    • Virtual biotech paper (https://www.science.org/doi/10.1126/science.aeg6779)

    • Paper2Agent paper (https://www.nature.com/articles/s41586-026-11044-y)

    37 min
  • EP 260: How AI is reshaping genomics, disease prediction, and biosecurity with Jeffrey Barrett of the University of Helsinki

    This week on The Genetics Podcast, Patrick is joined by Dr. Jeffrey Barrett, Group Leader at the Ellis Institute Finland and the University of Helsinki. They discuss using AI and federated biobank data to stratify common chronic diseases, how LLMs reading clinical notes in Finland's health registries can reveal treatment response, how AI is changing the way scientists research and train, and what the UK's COVID genome sequencing effort means for biosecurity.

    Show Notes

    0:00 Intro to The Genetics Podcast

    01:00 Welcome to Jeff 

    02:08 Jeff's research focus for his new lab, including molecular subtyping of common chronic diseases with AI

    06:18 Barriers to pooling biobank data across research environments for federated AI models

    11:00 Why Jeff expects larger datasets to make complex models better at predicting disease

    13:34 The three disease areas Jeff's lab will target first: cardiometabolic, inflammatory and neuropsychiatric

    19:41 Using LLMs to read clinician notes in Finland's health registries for treatment response

    24:50 How Jeff uses AI in his research and where humans still need to read and review

    31:08 Using Claude to understand papers and the gaps in its literature searches

    32:14 Jeff on AI solving open problems in mathematics and biology, and where researchers fit

    35:48 Simultaneous discoveries and why lab data generation still needs experts

    39:01 Jeff's COVID genome sequencing at Sanger and what it means for AI and biosecurity

    43:16  Closing remarks

    46 min
  • EP 259: A patient community driving awareness and research for Danon disease with Jenny Hsieh of the Danon Foundation

    Summary

    This week on The Genetics Podcast, Patrick is joined by Jenny Hsieh, Co-Founder and President of the Danon Foundation. They discuss how Danon disease affects males and females, why it is so often misdiagnosed, the current therapy landscape and research priorities, and how families can make informed decisions about gene therapy trials.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to Jenny 

    01:28 An overview of Danon disease

    02:34 Sex differences in Danon disease and severe disease in females

    05:15 Why Danon disease is misdiagnosed and how it may be spotted earlier

    08:50 Therapy pipeline for Danon and the Foundation's global patient coordination

    13:46 Origin story of the Danon Foundation

    18:10 Research priorities and the burden of Danon disease beyond the heart

    22:39 Raising genetic testing awareness among ophthalmologists and cardiologists for Danon disease

    25:20 Recognizing broader Danon symptoms and launching the first Danon Awareness Day

    29:37 Informed consent and trial literacy for families weighing gene therapy

    33:14 Patient-friendly trial experiences

    36:19 Ways to support Danon research

    37:37 Closing remarks

    Find out more

    • Danon Foundation

    39 min
  • EP 258: The mutations hiding in healthy tissues with Inigo Martincorena of the Wellcome Sanger Institute

    This week on The Genetics Podcast, Patrick is joined by Dr. Inigo Martincorena, Group Leader at the Wellcome Sanger Institute. They discuss the discovery of widespread cancer-driver mutations in normal tissue, the role of somatic mutations in autoimmune disease, new sequencing technologies transforming the field, and the therapeutic potential of targeting these mutations.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to Inigo 

    01:46 How Inigo's eyelid skin study revealed widespread cancer-driver mutations

    07:14 Findings from a follow-up study on esophageal tissue

    10:02 How NanoSeq technology scaled somatic mutation research across tissues

    12:34 The thyroid study linking somatic mutations to autoimmune disease

    17:07 How escaped B cell clones evolve into polyclonal autoimmune disease

    20:21 Immune gene mutations occurring in healthy aging lymphocytes

    21:21 Why driver mutation clones in normal tissue rarely become cancer

    24:16 Two therapeutic paradigms for targeting somatic mutations in disease

    28:13 Examples of somatic rescue mutations in the colon, liver, and blood

    29:20 Why clonal selection only occurs in dividing cell types

    31:20 The field's remaining blind spots in mobile immune cells and rare samples

    33:46 How new single-cell sequencing will link genotype to phenotype

    36:03 What Inigo has learned from collaborating across Sanger's expertise

    38:09 Closing remarks

    Find out more

    • Eyelid study

    • Esophagus study

    40 min
  • EP 257: Managing hereditary cancer risk and medical uncertainty with Marleah Dean Kruzel of the University of South Florida

    This week on The Genetics Podcast, Patrick is joined by Dr. Marleah Dean Kruzel, Professor of Communication at the University of South Florida. They discuss her personal path from watching breast cancer move through her family to testing positive for a hereditary mutation herself, the ART framework she developed for managing uncertainty, and the complexities of communicating genetic risk within families.

    Show Notes

    0:00 Intro to The Genetics Podcast

    00:59 Welcome to Marleah

    01:35 Marleah's family history of breast cancer across four generations

    02:48 Marleah's childhood living through her mother's five-year cancer battle

    04:26 Marleah's experience with genetic testing

    07:19 How a positive test result reshaped Marleah’s PhD research focus

    08:40 The central challenges of living with a positive test result 

    10:50 The ART framework for managing hereditary cancer uncertainty

    15:06 Applying the ART framework to Patrick’s experience with uncertainty and the importance of having a support system 

    19:53 Common misconceptions in how families communicate genetic risk

    23:54 The previvor identity and the chronic uncertainty it brings

    25:40 How Marleah has learned to accept and embrace uncertainty

    27:57 Balancing logic and emotion in hereditary cancer family planning

    31:28 How Marleah grounds her research tools in patients' lived experience

    33:21 How AI is eroding our capacity to sit with uncertainty

    35:57 Redesigning healthcare for a lifespan of genetic risk information

    38:10 Closing remarks

    40 min